Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 8/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24028679 | 0.93 | EGFR (0.55) | EGFRERBB2MAP2K1SRC | |
| SCHEMBL25616625 | 0.87 | MAP2K1 (0.47) | EGFRERBB2MAP2K1TP53SRC | |
| SCHEMBL24028702 | 0.79 | MAP2K1 (0.58) | EGFRERBB2MAP2K1SRCPDE4B | |
| SCHEMBL24028629 | 0.76 | EGFR (0.55) | EGFRERBB2MAP2K1SRC | |
| SCHEMBL24028703 | 0.75 | EGFR (0.54) | EGFRERBB2TP53SRCGAK | |
| SCHEMBL24028700 | 0.70 | GAK (0.39) | EGFRTP53SRCGAK | |
| SCHEMBL24028678 | 0.69 | EGFR (0.55) | EGFRERBB2CSF1R | |
| SCHEMBL24028680 | 0.69 | GAK (0.50) | EGFRGAK | |
| SCHEMBL27437241 | 0.66 | MAP2K1 (0.74) | EGFRERBB2MAP2K1SRCGAK | |
| SCHEMBL20782846 | 0.65 | MAP2K1 (0.72) | EGFRERBB2MAP2K1SRCGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | Vir Biotechnology, Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183188-A1 | ENPP1 MODULATORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | EGFR 4629/4885ERBB2 3535/4885MAP2K1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.